CTLA4 and melanoma: In keeping with reported ICB resistance in tumors with impaired IFN-γ signaling9–14, IFNγR1KO melanomas did not respond to anti-CTLA-4 treatment and continued to grow, whereas scrambled control melanomas were suppressed by anti-CTLA-4 (Fig. 1h).